Cencora, Inc. (NYSE:COR) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 10.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 322,092 shares of the company’s stock after selling 35,864 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.17% of Cencora worth $72,386,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its position in Cencora by 41.6% in the third quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company’s stock valued at $1,201,000 after buying an additional 1,568 shares during the last quarter. CX Institutional lifted its stake in Cencora by 8.0% during the 3rd quarter. CX Institutional now owns 8,868 shares of the company’s stock valued at $1,996,000 after acquiring an additional 654 shares during the period. NBC Securities Inc. boosted its holdings in shares of Cencora by 3.9% in the 3rd quarter. NBC Securities Inc. now owns 5,680 shares of the company’s stock valued at $1,278,000 after acquiring an additional 211 shares during the last quarter. Swedbank AB increased its stake in shares of Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after acquiring an additional 31,104 shares during the period. Finally, Regatta Capital Group LLC raised its holdings in shares of Cencora by 0.7% during the third quarter. Regatta Capital Group LLC now owns 8,576 shares of the company’s stock worth $1,930,000 after purchasing an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 over the last quarter. 10.80% of the stock is currently owned by insiders.

Cencora Trading Down 1.3 %

Shares of NYSE:COR opened at $243.55 on Thursday. The business’s 50 day moving average price is $238.70 and its 200-day moving average price is $237.21. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26. The firm has a market capitalization of $47.07 billion, a price-to-earnings ratio of 34.64, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.90%. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Analyst Ratings Changes

Several brokerages have weighed in on COR. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.